Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Recommends Ozurdex For Macular Edema; Off-Label Comparative Analysis Carries The Day

This article was originally published in The Pink Sheet Daily

Executive Summary

Allergan's intravitreal dexamethasone implant cleared by NICE for use in the NHS for macular edema; survives comparison with intravitreal Avastin with equivocal data.
Advertisement

Related Content

U.K. Cost Watchdog Rejects Lucentis’ Extended Use In Eye Disease
Novartis To Appeal NICE's Rejection Of Lucentis For Diabetic Macular Edema
Novartis To Appeal NICE's Rejection Of Lucentis For Diabetic Macular Edema
Lucentis And Avastin Stack Up In CATT, Forcing Genentech/Novartis To Play Defense
U.K.'s NICE Rejects Lucentis For Macular Edema; Avastin Remains Poised For Appraisal
U.K.'s Cost Regulator Wants Allergan To Compare Ozurdex With Avastin In Macular Edema
U.K.'s Cost Regulator Wants Allergan To Compare Ozurdex With Avastin In Macular Edema

Topics

Advertisement
UsernamePublicRestriction

Register

PS072474

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel